A new report from the Patented Medicine Prices Review Board (PMPRB) compares generic drug prices in Canada with those of other industrialized nations. The report was released in August 2013 and highlights changes in generic pricing between 2008 and the first quarter of (Q1-) 2011.

Although generic drug prices in Canada have been markedly reduced, mean international prices are still 35% lower than Canada's. Yet, the gap between brand-name and generic prices has increased in Canada. In Q1-2009 and Q1-2010 generic drugs were priced at 68% – 69% of the brand-name price; generics were priced at 64% in Q1-2011.

The analysis also conducted a bilateral comparison of Ontario formulary prices with those of 11 industrialized countries. Analysis focused on the top 50 selling generic drugs. These drugs accounted for nearly half of generic sales in the country. The results suggest that in Q1-2011, prices in Ontario for the top 50 generic drugs were higher than the corresponding foreign prices.  Only Australia and Switzerland had on average higher prices than Ontario.

The PMPRB issued a similar report in 2011, examining market structure trends of seven industrialized countries. Reported price ratios were well below parity and ranged from 42% (Sweden) to 73% (France) of Canadian prices. Despite recent attempts at the provincial level to address this disparity, the PMPRB's most recent report suggests that Ontarians — and Canadians — are still paying comparatively higher prices for generics.

Link to Report

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.